Swiss Group for Clinical Cancer Research

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Private

Established: 1965-01-01

Employees: -

Market Cap: -

Website: http://www.sakk.ch/

Clinical Trials

1st Line Durvalumab in PS 2 NSCLC Patients

Phase 2

Active, not recruiting

Conditions: NSCLC Stage IIIB
NSCLC Stage IV

Interventions: Drug: Durvalumab

First Posted Date: 2018-08-08

Last Posted Date: 2024-01-17

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 48

Registration Number: NCT03620669

Locations: 🇨🇭
Spital STS AG, Thun, Switzerland
🇨🇭
Kantonsspital Graubuenden, Chur, Switzerland
🇨🇭
Hopital Fribourgeois HFR, Fribourg, Switzerland

and more 8 locations

NAPAGE: NAb-PAclitaxel and GEmcitabine in Advanced Soft Tissue Sarcoma

Phase 1

Terminated

Conditions: Soft Tissue Sarcoma

Interventions: Drug: Nab-Paclitaxel
Drug: gemcitabine

First Posted Date: 2018-05-15

Last Posted Date: 2022-09-28

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 39

Registration Number: NCT03524898

Locations: 🇨🇭
Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland
🇨🇭
CHUV - Swiss Cancer Center Lausanne, Lausanne, Switzerland
🇨🇭
Kantonsspital St. Gallen, St. Gallen, Switzerland

and more 5 locations

Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma

Phase 2

Terminated

Conditions: Refractory Multiple Myeloma

Interventions: Drug: Pomalidomide
Drug: Dexamethasone

First Posted Date: 2018-05-11

Last Posted Date: 2021-06-10

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 34

Registration Number: NCT03520985

Locations: 🇨🇭
Onkozentrum Hirslanden Zürich, Zurich, Switzerland
🇨🇭
OnkoZentrum Zürich AG - Klinik im Park, Zürich, Switzerland
🇨🇭
Kantonspital Aarau, Aarau, Switzerland

and more 13 locations

Neoadjuvant and Adjuvant Durvalumab in Combination With Neoadjuvant Chemotherapy in Patients With Operable Urothelial Cancer.

Phase 2

Active, not recruiting

Conditions: Urothelial Cancer

Interventions: Drug: Neoadjuvant and adjuvant durvalumab

First Posted Date: 2018-01-23

Last Posted Date: 2024-08-28

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 61

Registration Number: NCT03406650

Locations: 🇨🇭
Universitaetsspital Basel, Basel, Switzerland
🇩🇪
Universitätsklinikum Düsseldorf, Düsseldorf, Germany
🇨🇭
Kantonspital Aarau, Aarau, Switzerland

and more 14 locations

TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors

Phase 1

Terminated

Conditions: Advanced Solid Tumors

Interventions: Drug: Caelyx
Drug: TLD-1

First Posted Date: 2018-01-02

Last Posted Date: 2024-12-02

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 12

Registration Number: NCT03387917

Locations: 🇨🇭
Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland
🇨🇭
Inselspital Bern, Bern, Switzerland
🇨🇭
Kantonsspital Graubünden, Chur, Switzerland

and more 2 locations

Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma

Phase 2

Active, not recruiting

Conditions: Renal Cell Carcinoma

Interventions: Drug: nivolumab
Drug: ipilimumab

First Posted Date: 2017-09-29

Last Posted Date: 2024-05-14

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 74

Registration Number: NCT03297593

Locations: 🇨🇭
Universitätsspital Basel, Basel, Switzerland
🇨🇭
Spital Thurgau, Frauenfeld, Switzerland
🇨🇭
Kantonsspital Baselland Bruderholz, Bruderholz, Switzerland

and more 11 locations

Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma.

Phase 2

Completed

Conditions: Malignant Pleural Mesothelioma, Advanced

Interventions: Drug: Lurbinectedin

First Posted Date: 2017-07-11

Last Posted Date: 2021-07-14

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 42

Registration Number: NCT03213301

Locations: 🇨🇭
Kantonsspital Graubuenden, Chur, Switzerland
🇨🇭
Regionalspital Thun, Thun, Switzerland
🇮🇹
A.O. SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy

and more 5 locations

Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC.

Phase 1

Completed

Conditions: Lung Cancer
Advanced Non-small Cell Lung Cancer
KRAS Gene Mutation

Interventions: Drug: Binimetinib
Drug: Pemetrexed
Drug: Cisplatin

First Posted Date: 2016-11-16

Last Posted Date: 2021-07-14

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 18

Registration Number: NCT02964689

Locations: 🇨🇭
Kantonsspital Graubuenden, Chur, Switzerland
🇨🇭
Kantonsspital St. Gallen, St. Gallen, Switzerland
🇨🇭
IOSI Ospedale Regionale di Bellinzona e Valli, Bellinzona, Switzerland

and more 1 locations

SAKK 08/15 - PROMET - Salvage Radiotherapy +/- Metformin for Patients With Prostate Cancer After Prostatectomy

Phase 2

Terminated

Conditions: Prostate Cancer

Interventions: Drug: Metformin
Radiation: Salvage Radiotherapy SRT

First Posted Date: 2016-10-26

Last Posted Date: 2022-04-14

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 112

Registration Number: NCT02945813

Locations: 🇫🇷
Centre de lutte contre le cancer Léon Bérard, Lyon, France
🇫🇷
Centre Hospitalier Régional Universitaire (CHRU) Jean Minjoz, Besançon, France
🇨🇭
Hôpitaux Universitaires Genève HUG, Geneva, Switzerland

and more 24 locations

ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents.

Phase 2

Terminated

Conditions: Prostate Cancer Metastatic
Prostate Cancer

Interventions: Drug: ODM-201
Other: Placebo

First Posted Date: 2016-10-14

Last Posted Date: 2024-03-13

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 92

Registration Number: NCT02933801

Locations: 🇨🇭
Hôpital du Valais (Sion et Martigny), Sion, Switzerland
🇫🇷
Centre Eugène Marquis, Rennes, France
🇮🇹
Istituto Nazionale dei Tumori - IRCCS Fondazione Pascale S.C., Napoli, Italy

and more 29 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy